A qualitative prognostic biomarker for melanoma based on the relative methylation orderings of CpG loci

Skin cutaneous melanoma (SKCM) is an aggressive tumor with a poor prognosis. We developed SKCM-P8, a novel qualitative prognostic biomarker based on the relative methylation orderings of eight pairs of loci. Analysis of a training cohort and two independent validation datasets revealed a significant...

Full description

Saved in:
Bibliographic Details
Main Authors: Yue Huo, Yaru Gao, Jiayi Ruan, Lingli Wang, Hongdong Li, Guini Hong
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Epigenetics
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/15592294.2025.2487316
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850272937521709056
author Yue Huo
Yaru Gao
Jiayi Ruan
Lingli Wang
Hongdong Li
Guini Hong
author_facet Yue Huo
Yaru Gao
Jiayi Ruan
Lingli Wang
Hongdong Li
Guini Hong
author_sort Yue Huo
collection DOAJ
description Skin cutaneous melanoma (SKCM) is an aggressive tumor with a poor prognosis. We developed SKCM-P8, a novel qualitative prognostic biomarker based on the relative methylation orderings of eight pairs of loci. Analysis of a training cohort and two independent validation datasets revealed a significant difference in overall survival between high- and low-risk groups stratified by SKCM-P8 (p < 0.05, log-rank test), with average area under the curve values of 0.83, 0.80, and 0.61, respectively. The differential methylation loci between high- and low-risk patients were enriched in immune-related biological processes and signaling pathways. Furthermore, low-risk patients exhibited higher CD8+ T cells and B levels, while high-risk patients had higher monocytes. The methylation levels of SKCM-P8 were also correlated with immune cell levels, indicating that they can reflect prognosis-related immune information. The low-risk group had a significantly higher mutation burden (p < 0.05, Wilcoxon test), suggesting potential benefits from immune checkpoint inhibitors. Patients stratified by SKCM-P8 displayed differential responses to therapy and immunotherapy (p < 0.05, Wilcoxon test), with low-risk patients showing better sensitivity and response. Furthermore, SKCM-P8 demonstrated super-predictive accuracy compared to six published models. Overall, SKCM-P8 offers a promising tool for predicting prognosis and guiding therapeutic decisions in SKCM.
format Article
id doaj-art-1c42b6e620ed4e319558db11df67a487
institution OA Journals
issn 1559-2294
1559-2308
language English
publishDate 2025-12-01
publisher Taylor & Francis Group
record_format Article
series Epigenetics
spelling doaj-art-1c42b6e620ed4e319558db11df67a4872025-08-20T01:51:39ZengTaylor & Francis GroupEpigenetics1559-22941559-23082025-12-0120110.1080/15592294.2025.2487316A qualitative prognostic biomarker for melanoma based on the relative methylation orderings of CpG lociYue Huo0Yaru Gao1Jiayi Ruan2Lingli Wang3Hongdong Li4Guini Hong5School of Public Health and Health Management, Gannan Medical University, Ganzhou, ChinaSchool of Public Health and Health Management, Gannan Medical University, Ganzhou, ChinaSchool of Medical Information Engineering, Gannan Medical University, Ganzhou, ChinaSchool of Medical Information Engineering, Gannan Medical University, Ganzhou, ChinaSchool of Medical Information Engineering, Gannan Medical University, Ganzhou, ChinaSchool of Medical Information Engineering, Gannan Medical University, Ganzhou, ChinaSkin cutaneous melanoma (SKCM) is an aggressive tumor with a poor prognosis. We developed SKCM-P8, a novel qualitative prognostic biomarker based on the relative methylation orderings of eight pairs of loci. Analysis of a training cohort and two independent validation datasets revealed a significant difference in overall survival between high- and low-risk groups stratified by SKCM-P8 (p < 0.05, log-rank test), with average area under the curve values of 0.83, 0.80, and 0.61, respectively. The differential methylation loci between high- and low-risk patients were enriched in immune-related biological processes and signaling pathways. Furthermore, low-risk patients exhibited higher CD8+ T cells and B levels, while high-risk patients had higher monocytes. The methylation levels of SKCM-P8 were also correlated with immune cell levels, indicating that they can reflect prognosis-related immune information. The low-risk group had a significantly higher mutation burden (p < 0.05, Wilcoxon test), suggesting potential benefits from immune checkpoint inhibitors. Patients stratified by SKCM-P8 displayed differential responses to therapy and immunotherapy (p < 0.05, Wilcoxon test), with low-risk patients showing better sensitivity and response. Furthermore, SKCM-P8 demonstrated super-predictive accuracy compared to six published models. Overall, SKCM-P8 offers a promising tool for predicting prognosis and guiding therapeutic decisions in SKCM.https://www.tandfonline.com/doi/10.1080/15592294.2025.2487316Melanomaprognosisrelative methylation orderings
spellingShingle Yue Huo
Yaru Gao
Jiayi Ruan
Lingli Wang
Hongdong Li
Guini Hong
A qualitative prognostic biomarker for melanoma based on the relative methylation orderings of CpG loci
Epigenetics
Melanoma
prognosis
relative methylation orderings
title A qualitative prognostic biomarker for melanoma based on the relative methylation orderings of CpG loci
title_full A qualitative prognostic biomarker for melanoma based on the relative methylation orderings of CpG loci
title_fullStr A qualitative prognostic biomarker for melanoma based on the relative methylation orderings of CpG loci
title_full_unstemmed A qualitative prognostic biomarker for melanoma based on the relative methylation orderings of CpG loci
title_short A qualitative prognostic biomarker for melanoma based on the relative methylation orderings of CpG loci
title_sort qualitative prognostic biomarker for melanoma based on the relative methylation orderings of cpg loci
topic Melanoma
prognosis
relative methylation orderings
url https://www.tandfonline.com/doi/10.1080/15592294.2025.2487316
work_keys_str_mv AT yuehuo aqualitativeprognosticbiomarkerformelanomabasedontherelativemethylationorderingsofcpgloci
AT yarugao aqualitativeprognosticbiomarkerformelanomabasedontherelativemethylationorderingsofcpgloci
AT jiayiruan aqualitativeprognosticbiomarkerformelanomabasedontherelativemethylationorderingsofcpgloci
AT lingliwang aqualitativeprognosticbiomarkerformelanomabasedontherelativemethylationorderingsofcpgloci
AT hongdongli aqualitativeprognosticbiomarkerformelanomabasedontherelativemethylationorderingsofcpgloci
AT guinihong aqualitativeprognosticbiomarkerformelanomabasedontherelativemethylationorderingsofcpgloci
AT yuehuo qualitativeprognosticbiomarkerformelanomabasedontherelativemethylationorderingsofcpgloci
AT yarugao qualitativeprognosticbiomarkerformelanomabasedontherelativemethylationorderingsofcpgloci
AT jiayiruan qualitativeprognosticbiomarkerformelanomabasedontherelativemethylationorderingsofcpgloci
AT lingliwang qualitativeprognosticbiomarkerformelanomabasedontherelativemethylationorderingsofcpgloci
AT hongdongli qualitativeprognosticbiomarkerformelanomabasedontherelativemethylationorderingsofcpgloci
AT guinihong qualitativeprognosticbiomarkerformelanomabasedontherelativemethylationorderingsofcpgloci